TD Cowen analyst Tyler Van Buren has maintained their bullish stance on ORKA stock, giving a Buy rating today.
Tyler Van Buren has given his Buy rating due to a combination of factors related to Oruka Therapeutics’ promising developments in their drug pipeline. The standout feature is the impressive preclinical data for ORKA-002, which demonstrated a significantly extended half-life in non-human primates compared to existing treatments like Bimzelx. This extended half-life suggests the potential for less frequent dosing in humans, which could enhance patient compliance and market appeal.
Additionally, the projected pharmacokinetics for ORKA-002 indicate it could achieve a rapid onset and maintain therapeutic levels with fewer doses, potentially outperforming current market leaders. The innovative design of the Phase IIa trial for ORKA-001, with its ‘treat and extend’ arm, further underscores the company’s strategic approach to drug development. These factors collectively contribute to a positive outlook for Oruka Therapeutics, justifying the Buy rating.
Van Buren covers the Healthcare sector, focusing on stocks such as Regeneron, BridgeBio Pharma, and Arcutis Biotherapeutics. According to TipRanks, Van Buren has an average return of -2.3% and a 39.79% success rate on recommended stocks.
In another report released today, Stifel Nicolaus also reiterated a Buy rating on the stock with a $49.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com